FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994459308> ?p ?o ?g. }

• W1994459308 endingPage "1405" @default.
• W1994459308 startingPage "1401" @default.
• W1994459308 abstract "We determine the effects of treatment with rofecoxib and placebo in patients with chronic prostatitis.Patients diagnosed with chronic nonbacterial prostatitis were randomized to 6 weeks of 25 or 50 mg., rofecoxib or placebo in a double-blind multicenter study with a 1-week run in of placebo. End points included the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) (average pain score item 4 primary end point), and patient global assessment questions of pain, disease activity and response to therapy.A total of 161 patients were randomized in the study. The NIH-CPSI total, domain and pain scores significantly decreased from baseline in all groups and, although the mean scores numerically favored the rofecoxib groups, the difference was not significantly different among groups. There was a trend for the percentage of patients with a 25% (or 6 point) improvement in total score being superior on rofecoxib versus placebo with the difference being significantly different (p <0.05) for the 50 mg. rofecoxib group. Patient global assessment of pain, response to therapy and disease activity also favored rofecoxib over placebo (p <0.05, p = 0.07, p = 0.06, respectively). Of the patients 79% on 50 mg. rofecoxib versus 59% on placebo reported no or mild pain, and 56% of patients on 50 mg. rofecoxib versus 27% on placebo experienced significant improvement in quality of life (p <0.005). Rofecoxib was generally well tolerated.To our knowledge this study is the first to evaluate rofecoxib versus placebo in patients with prostatitis and the first large multicenter treatment study to use the NIH-CPSI. Subjective assessment with patient global questions may be more sensitive to change than the NIH-CPSI and, therefore, may be a better tool to use in future therapeutic trials. Although 6 weeks of rofecoxib treatment appear to benefit many men diagnosed with chronic prostatitis/chronic pelvic pain syndrome further studies are needed." @default.
• W1994459308 created "2016-06-24" @default.
• W1994459308 creator A5003890871 @default.
• W1994459308 creator A5005637307 @default.
• W1994459308 creator A5006234197 @default.
• W1994459308 creator A5007987589 @default.
• W1994459308 creator A5012643629 @default.
• W1994459308 creator A5028552239 @default.
• W1994459308 creator A5028562399 @default.
• W1994459308 creator A5034811772 @default.
• W1994459308 creator A5037636679 @default.
• W1994459308 creator A5040028162 @default.
• W1994459308 creator A5041384721 @default.
• W1994459308 creator A5049019006 @default.
• W1994459308 creator A5049447136 @default.
• W1994459308 creator A5052129992 @default.
• W1994459308 creator A5053019771 @default.
• W1994459308 creator A5057746630 @default.
• W1994459308 creator A5058166573 @default.
• W1994459308 creator A5061671128 @default.
• W1994459308 creator A5062425310 @default.
• W1994459308 creator A5063690905 @default.
• W1994459308 creator A5063808159 @default.
• W1994459308 creator A5068720436 @default.
• W1994459308 creator A5069637004 @default.
• W1994459308 creator A5070059966 @default.
• W1994459308 creator A5072698971 @default.
• W1994459308 creator A5075123465 @default.
• W1994459308 creator A5078385927 @default.
• W1994459308 creator A5081214299 @default.
• W1994459308 creator A5082529315 @default.
• W1994459308 creator A5083040184 @default.
• W1994459308 date "2003-04-01" @default.
• W1994459308 modified "2023-10-02" @default.
• W1994459308 title "A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis" @default.
• W1994459308 cites W1837402230 @default.
• W1994459308 cites W1966474913 @default.
• W1994459308 cites W1973214716 @default.
• W1994459308 cites W1984891090 @default.
• W1994459308 cites W1997517088 @default.
• W1994459308 cites W2028626284 @default.
• W1994459308 cites W2056420697 @default.
• W1994459308 cites W2065642192 @default.
• W1994459308 cites W2076961118 @default.
• W1994459308 cites W2077215956 @default.
• W1994459308 cites W2093424875 @default.
• W1994459308 cites W2097199316 @default.
• W1994459308 cites W2125680538 @default.
• W1994459308 doi "https://doi.org/10.1097/01.ju.0000054983.45096.16" @default.
• W1994459308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12629372" @default.
• W1994459308 hasPublicationYear "2003" @default.
• W1994459308 type Work @default.
• W1994459308 sameAs 1994459308 @default.
• W1994459308 citedByCount "133" @default.
• W1994459308 countsByYear W19944593082012 @default.
• W1994459308 countsByYear W19944593082013 @default.
• W1994459308 countsByYear W19944593082014 @default.
• W1994459308 countsByYear W19944593082015 @default.
• W1994459308 countsByYear W19944593082016 @default.
• W1994459308 countsByYear W19944593082017 @default.
• W1994459308 countsByYear W19944593082018 @default.
• W1994459308 countsByYear W19944593082019 @default.
• W1994459308 countsByYear W19944593082020 @default.
• W1994459308 countsByYear W19944593082021 @default.
• W1994459308 countsByYear W19944593082022 @default.
• W1994459308 countsByYear W19944593082023 @default.
• W1994459308 crossrefType "journal-article" @default.
• W1994459308 hasAuthorship W1994459308A5003890871 @default.
• W1994459308 hasAuthorship W1994459308A5005637307 @default.
• W1994459308 hasAuthorship W1994459308A5006234197 @default.
• W1994459308 hasAuthorship W1994459308A5007987589 @default.
• W1994459308 hasAuthorship W1994459308A5012643629 @default.
• W1994459308 hasAuthorship W1994459308A5028552239 @default.
• W1994459308 hasAuthorship W1994459308A5028562399 @default.
• W1994459308 hasAuthorship W1994459308A5034811772 @default.
• W1994459308 hasAuthorship W1994459308A5037636679 @default.
• W1994459308 hasAuthorship W1994459308A5040028162 @default.
• W1994459308 hasAuthorship W1994459308A5041384721 @default.
• W1994459308 hasAuthorship W1994459308A5049019006 @default.
• W1994459308 hasAuthorship W1994459308A5049447136 @default.
• W1994459308 hasAuthorship W1994459308A5052129992 @default.
• W1994459308 hasAuthorship W1994459308A5053019771 @default.
• W1994459308 hasAuthorship W1994459308A5057746630 @default.
• W1994459308 hasAuthorship W1994459308A5058166573 @default.
• W1994459308 hasAuthorship W1994459308A5061671128 @default.
• W1994459308 hasAuthorship W1994459308A5062425310 @default.
• W1994459308 hasAuthorship W1994459308A5063690905 @default.
• W1994459308 hasAuthorship W1994459308A5063808159 @default.
• W1994459308 hasAuthorship W1994459308A5068720436 @default.
• W1994459308 hasAuthorship W1994459308A5069637004 @default.
• W1994459308 hasAuthorship W1994459308A5070059966 @default.
• W1994459308 hasAuthorship W1994459308A5072698971 @default.
• W1994459308 hasAuthorship W1994459308A5075123465 @default.
• W1994459308 hasAuthorship W1994459308A5078385927 @default.
• W1994459308 hasAuthorship W1994459308A5081214299 @default.
• W1994459308 hasAuthorship W1994459308A5082529315 @default.
• W1994459308 hasAuthorship W1994459308A5083040184 @default.
• W1994459308 hasConcept C121608353 @default.

• next